Columbus Circle Capital Corp II
CMII
NASDAQ10.06
USD
-0.05
- -
CIK
0002088805
ISIN
KYG2296M1033
CUSIP
G2296M103
Return %
Stock
S&P500
1Y
2.55
18.21
3Y
2.55
63.29
5Y
2.55
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gary Quin
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 3 Columbus Circle New York NY United States of America 10019
- IPO Date
- Feb 11, 2026
- CIK
- 0002088805
- Similar Companies
- Business
- CM Life Sciences II Inc. (CMII) is a blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in the fragmented life sciences industry, including life sciences tools; synthetic biology; and diagnostics. Sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, the company is led by Chief Executive Officer Eli Casdin and Chairman Keith Meister, with a board featuring life sciences experts such as Kevin Conroy, Troy Cox, Jason Kelly, Ph.D., and Stephen Quake, Ph.D. Incorporated in 2020 as a Delaware corporation and headquartered in New York, New York, CM Life Sciences II Inc. does not have significant independent operations or products and services beyond pursuing and executing its targeted business combination. In February 2021, the company completed an upsized initial public offering of 27.6 million units at $10.00 per unit, raising $276 million in gross proceeds, with 100% of IPO cash placed in trust. In March 2021, it announced a definitive business combination agreement with SomaLogic, Inc., a proteomics company offering the SomaScan platform for high-throughput protein biomarker discovery, measurement, and clinical diagnostics using modified aptamer (SOMAmer) technology; the transaction, valued at approximately $1.23 billion including up to $651 million in cash proceeds, was approved by shareholders and closed in September 2021, resulting in SomaLogic becoming a publicly listed company under the ticker SLGC on Nasdaq while CM Life Sciences II Inc. shares ceased active trading. Subsequently, in October 2023, SomaLogic agreed to an all-stock merger with Standard BioTools Inc., completed in January 2024, under which SomaLogic shareholders received 1.11 shares of Standard BioTools common stock per share and the combined entity positioned itself as a leader in multi-omics tools for research with enhanced scale, over $500 million in cash, and targeted $80 million in annual cost synergies by 2026; CMII is now delisted. The company operates with a global focus through its target sectors but maintains no ongoing geographic operations post-combination.
Columbus Circle Capital Corp II (CMII) M&A Call Transcript
Elroy Air to Become Publicly Traded Company via Business Combination with Inflection Point-led SPAC